Full-Time

Biotechnician 1

Updated on 8/1/2026

BeOne

BeOne

1,001-5,000 employees

Global oncology therapeutics discovery, development, manufacturing

Compensation Overview

$25.48 - $33.48/hr

+ Annual bonus plan + Discretionary equity awards + Employee Stock Purchase Plan

Hopewell, NJ, USA

In Person

International and domestic travel may be required.

Category
Biology & Biotech (1)
Required Skills
GMP
Word/Pages/Docs
Data Analysis
Excel/Numbers/Sheets

Get referred to BeOne

See people who can refer or advise you

Requirements
  • High school education or GED is required.
  • The employee must demonstrate good verbal and written communication.
  • The employee must be able to work in a fast-paced, dynamic environment with competing priorities.
  • The employee must be able to collaborate within and between diverse groups.
  • The employee must proactively identify and implement continuous improvement opportunities.
  • The employee must have an aptitude for learning moderately complex technical systems.
  • The employee must be able to receive and incorporate feedback.
  • The employee must be familiar with computer-based systems and must use Microsoft Word, Microsoft Excel, and Microsoft PowerPoint.
  • The employee must be able to stand for up to 8 to 10 hours per day.
  • The employee must be able to reach above shoulder level, bend or stoop, push or pull, and handle or grip frequently.
  • The employee must be able to work scheduled 40-hour weeks and overtime as needed.
  • The employee must be comfortable working in varying temperatures.
  • The employee must be able to lift up to 40 pounds and frequently lift, push, pull, and carry.
  • The employee must be able to perform repetitive wrist, hand, and finger movements.
  • The employee must work with hazardous materials and chemicals.
  • The employee must be willing to work any shift.
  • The employee must be willing to travel internationally and domestically as required.
Responsibilities
  • Support the startup phase of the Hopewell manufacturing facility and then execute and support cGMP manufacturing operations.
  • Perform design reviews.
  • Support equipment selection, procurement, and testing.
  • Develop and execute protocols.
  • Perform acceptance testing and debug equipment and automation.
  • Provide technical training.
  • Follow cGMP procedures to support manufacturing execution and automated recipes.
  • Prepare and transfer media, including filtration.
  • Sample, monitor, and transfer cell cultures.
  • Perform harvest operations.
  • Prepare and transfer buffers, including filtration.
  • Operate and clean chromatography and filtration systems.
  • Troubleshoot equipment and processes.
  • Identify and report deviations, draft deviation investigations, and support investigation closure.
  • Draft, present, and close change controls.
  • Develop and optimize cGMP procedures.
  • Request, stage, and verify materials for production activities.
  • Set up and prepare equipment for formulation and filling.
  • Perform final filtration and formulate drug product.
  • Aseptically fill vials inside a Grade A isolator using automated filling equipment.
  • Perform in-process visual inspection for quality assurance.
  • Label and package finished drug product in compliance with cGMP.
  • Complete batch documentation and review records for accuracy.
  • Support routine cleanroom operations, equipment sanitization, and environmental monitoring.
  • Assist in deviation investigations and participate in CAPA implementation as needed.
  • Operate the distributed computer system.
  • Operate Clean-in-Place systems, Steam-in-Place skids, caustic skids, autoclaves, part washers, filter integrity testers, and biowelders.
  • Operate the SoloVPE protein concentration analyzer.
  • Clean the facility.
  • Collect samples for environmental monitoring.
  • Remove process waste.
  • Support the supervisor in managing day-to-day activities, including staff availability and task load.
  • Escalate issues and concerns in a timely manner.
Desired Qualifications
  • An Associate of Science, Bachelor of Science, or Bachelor of Arts degree in a science-related field or biopharmaceutical field, or equivalent technical experience, is preferred.
  • Previous experience with biopharmaceutical manufacturing, cGMP operations, or related technical systems is desirable based on the stated preference for equivalent technical experience.

BeOne Medicines develops and commercializes cancer therapies for patients worldwide, focusing on hematologic cancers and solid tumors. Its products, including Brukinsa, are sold globally and supported by licensing partnerships, with internal R&D and clinical development driving a broad late-stage pipeline. BeOne differentiates itself by leveraging a large-scale clinical trial network and cost-efficient global drug development to achieve high margins while pursuing large-market indications. The company aims to expand into immunology and solid tumors while maintaining strong investment in R&D to make high-impact, accessible oncology treatments available in more than 45 countries.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Dongcheng District, China

Founded

2010

Get referred to BeOne

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • BRUKINSA and sonrotoclax can expand fixed-duration CLL treatment standards.
  • BGB-43395 and BG-C9074 deepen breast-cancer pipeline optionality.
  • Q1 2026 revenue reached $1.5 billion, supporting broader R&D investment.

What critics are saying

  • Revenue still depends heavily on BRUKINSA, exposing the company to concentration risk.
  • Solid-tumor programs remain early-stage, with limited efficacy and tolerability data.
  • Insider stock sales can pressure sentiment despite the 10b5-1 plan.

What makes BeOne unique

  • Global oncology platform spans hematology, immunology, and solid tumors.
  • BRUKINSA anchors a leading hematology franchise across multiple approved markets.
  • Large global trial network enables faster, more cost-efficient clinical development.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

401(k) Retirement Plan

Wellness Program

Paid Vacation

Growth & Insights and Company News

Headcount

6 month growth

-7%

1 year growth

-9%

2 year growth

-3%
Yahoo Finance
Apr 10th, 2026
Amgen's lung cancer drug tarlatamab wins China approval, seen as $2B+ opportunity

Amgen's lung cancer drug tarlatamab has received approval from China's National Medical Products Administration, according to its development partner BeOne Medicines. The drug is a targeted immunotherapy for adults with extensive-stage small cell lung cancer that has progressed despite chemotherapy. Sold as Imdelltra in the US, tarlatamab is a bispecific antibody designed to connect cancer cells with immune cells, enabling the body's immune system to destroy the cancer. Neither Amgen nor Hong Kong-listed BeOne provided details on launch date or pricing for the Chinese market. Wall Street analysts estimate tarlatamab could generate annual sales exceeding $2 billion for Amgen.

Yahoo Finance
Feb 26th, 2026
BeOne Medicines reports $1.5B revenue, up 33% despite EPS miss in Q4

BeOne Medicines reported $1.5 billion in revenue for the quarter ended December 2025, a 32.8% year-over-year increase, beating the Zacks Consensus Estimate by 3.19%. The company posted earnings per share of $0.58, compared to a loss of $1.43 in the prior year, though this fell short of the $1.60 consensus estimate. Net product revenues reached $1.48 billion, exceeding the $1.45 billion analyst estimate. BRUKINSA generated $1.15 billion, surpassing the $1.09 billion estimate, whilst TEVIMBRA contributed $182 million, slightly below the $191.33 million forecast. The stock has returned 0.6% over the past month, matching the S&P 500's performance. BeOne currently holds a Zacks Rank of 2, indicating potential outperformance.

Business Wire
Feb 26th, 2026
BeOne Medicines reports $5.3B full-year revenue as BRUKINSA sales surge 49%

BeOne Medicines reported fourth quarter 2025 product revenues of $1.5 billion and full-year revenues of $5.3 billion, representing growth of 32% and 40% year-over-year respectively. Product revenue accounted for 99% of total revenue. BRUKINSA, the company's BTK inhibitor, achieved global sales of $1.1 billion in Q4 and $3.9 billion for the full year, up 38% and 49% respectively. US sales reached $845 million in Q4 and $2.8 billion annually. TEVIMBRA generated $182 million in Q4 and $737 million for the year. The company reported GAAP net income of $67 million in Q4 and $287 million for the full year, compared to losses in prior-year periods. Free cash flow reached $942 million for 2025, up $1.6 billion year-over-year. BeOne provided 2026 guidance of $6.2–6.4 billion in total revenue and $1.4–1.5 billion in non-GAAP operating income.

Yahoo Finance
Feb 2nd, 2026
BeOne Medicines trades at $340 with 51% annual return amid undervaluation signals

BeOne Medicines is trading at $340.38, representing a 9.44% year-to-date gain and 51.29% total shareholder return over the past year, though recent performance has been mixed with a one-day decline and flat weekly performance. The company appears undervalued against an estimated fair value of $401.52, based on strong revenue growth fundamentals. BeOne reported 41% year-over-year revenue growth in Q2 and raised full-year guidance to $5–5.3 billion, driven by demand for its oncology therapy BRUKINSA. The valuation narrative assumes continued aggressive expansion and rising profitability, supported by an ageing population and increased global healthcare spending. However, risks include potential competition affecting BRUKINSA revenues and possible delays in late-stage trials or regulatory approvals.

TipRanks
Nov 20th, 2025
BeOne Medicines Secures $1 Billion Financing Agreement - TipRanks.com

BeOne Medicines ( ($ONC) ) has shared an announcement. On November 13, 2025, BeOne Medicines Ltd. entered into a Facilities Agreement with HSBC and other financial ...